Author

A. Amara

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Approach:statistical model· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

L. Bonnet-Madin· 3 shared L. Meertens· 3 shared C. Delaugerre· 2 shared P.-O. Vidalain· 2 shared V. Soumelis· 2 shared A. Brugier· 1 shared A. Labeau· 1 shared A. Lefevre-Utile· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

L. Bonnet-Madin

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

RACK1 associates with RNA-binding proteins Vigilin and SERBP1 to control dengue virus replication

A. Brugier, M.-L. Hafirassou, M. Pourcelot, M. Baldaccini, L. Couture, V. Kril, B. Kuemmerer, S. Gallois-Montbrun, L. Bonnet-Madin, S. Pfeffer, P.-O. Vidalain, C. Delaugerre, L. Meertens, A. Amara

This study identifies RACK1 as a host factor that recruits Vigilin and SERBP1 to facilitate dengue virus replication by linking viral RNA to the translation machinery.

bioRxiv · Oct 28, 2021 · PreprintMicrobiology

Characterization and functional interrogation of SARS-CoV-2 RNA interactome

A. Labeau, A. Lefevre-Utile, L. Bonnet-Madin, L. Fery-Simonian, V. Soumelis, V. Lotteau, P.-O. Vidalain, A. Amara, L. Meertens

This study identifies 142 RNA-binding proteins interacting with SARS-CoV-2 RNA and finds many are proviral, offering potential drug targets for antiviral therapies.

bioRxiv · Mar 23, 2021Microbiology

SARS-CoV-2 induces human plasmacytoid pre-dendritic cell diversification via UNC93B and IRAK4

F. Onodi, L. Bonnet-Madin, L. Meertens, L. Karpf, J. Poirot, S.-Y. Zhang, c. picard, A. Puel, E. Jouanguy, Q. Zhang, J. LeGoff, J.-M. Molina, C. Delaugerre, J.-L. Casanova, A. AMARA, V. Soumelis

This study shows SARS-CoV-2 activates human plasmacytoid pre-dendritic cells (pDC) via UNC93B and IRAK4, leading to interferon and cytokine production.

bioRxiv · Jul 10, 2020Immunology

Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine

S. Walimbwa, M. Lamorde, C. Waitt, J. Kaboggoza, L. Else, P. Byakika-Kibwika, A. Amara, J. Gini, M. Winterberg, J. Chiong, J. Tarning, S. H. Khoo

This study investigates drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine, finding no significant changes in most drug concentrations but a decrease in dolutegravir trough levels with both combinations.

bioRxiv · Jun 20, 2018Pharmacology & Toxicology